Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Insmed Incorporated INSM
$18.62
-$0.32 (-1.74%)
На 18:00, 12 мая 2023
+200.75%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2544475301.00000000
-
week52high
28.94
-
week52low
16.04
-
Revenue
245358000
-
P/E TTM
-5
-
Beta
1.53010300
-
EPS
-4.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Goldman Sachs | Buy | 27 апр 2022 г. | |
| SVB Leerink | Outperform | Outperform | 22 февр 2022 г. |
| JP Morgan | Overweight | 06 дек 2021 г. | |
| SVB Leerink | Outperform | Outperform | 27 окт 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 25 окт 2022 г. |
| Cowen & Co. | Outperform | Outperform | 21 окт 2022 г. |
| B of A Securities | Buy | 18 ноя 2022 г. | |
| Mizuho | Buy | 09 дек 2022 г. | |
| Barclays | Overweight | 08 дек 2022 г. | |
| Barclays | Overweight | 07 дек 2022 г. | |
| Goldman Sachs | Buy | Buy | 09 янв 2023 г. |
| Barclays | Overweight | Overweight | 20 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wise John Drayton | D | 77272 | 779 | 10 янв 2023 г. |
| Schaeffer Orlov S Nicole | D | 72159 | 2435 | 10 янв 2023 г. |
| Smith Michael Alexander | D | 54332 | 1836 | 10 янв 2023 г. |
| Flammer Martina M.D. | D | 72763 | 3439 | 10 янв 2023 г. |
| Lewis William | D | 265067 | 6994 | 10 янв 2023 г. |
| Adsett Roger | D | 135487 | 3194 | 10 янв 2023 г. |
| Bonstein Sara | D | 66031 | 2857 | 10 янв 2023 г. |
| Wise John Drayton | A | 34860 | 34860 | 05 янв 2023 г. |
| Wise John Drayton | A | 78051 | 7598 | 05 янв 2023 г. |
| Wise John Drayton | D | 70453 | 1160 | 05 янв 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2800880 | -52544 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 2174510 | 62320 | 31 авг 2020 г. |
| SPDR S&P Biotech ETF | 2040380 | -104964 | 31 авг 2020 г. |
| Vanguard Small-Cap Index Fund | 2475280 | -14700 | 31 июл 2020 г. |
| Fidelity Advisor Growth Opportunities Fund | 1726920 | 0 | 31 июл 2020 г. |
| T. Rowe Price New Horizons Fund | 2014460 | 1033330 | 30 июн 2020 г. |
| T. Rowe Price Health Sciences Fund | 1743700 | 947284 | 30 июн 2020 г. |
| T. Rowe Price Small Cap Stock Fund | 1570380 | -6100 | 30 июн 2020 г. |
| Janus Henderson Global Life Sciences Fund (US) | 1752940 | -526550 | 31 мар 2020 г. |
| Janus Henderson Henderson Research Fund | 1552010 | -264297 | 31 мар 2020 г. |
Новостная лента
Insmed Incorporated (INSM) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 18:21
Insmed Incorporated (NASDAQ:INSM ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bryan Dunn - Head of Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Nick Lenard - JPMorgan Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Jennifer Kim - Cantor Fitzgerald Leon Wang - Barclays Stephen Willey - Stifel Jason Zemansky - Bank of America Liisa Bayko - Evercore Michael Riad - Morgan Stanley Operator Good morning, and welcome to the Insmed First Quarter 2023 Financial Results. My name is Nandaja, and I will be your operator today.
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 10:41
Insmed (INSM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $0.80 per share a year ago.
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
PRNewsWire
24 мар 2023 г. в 16:22
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease (COPD) to Be Shared in Oral Presentation— —Researchers to Present Subgroup Analysis from Phase 2 WILLOW Study Evaluating Brensocatib Treatment Outcomes by Disease Severity in Patients with Bronchiectasis— BRIDGEWATER, N.J. , March 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—ARIKAYCE ® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C.
Insmed Incorporated (INSM) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 17:20
Insmed Incorporated (NASDAQ:INSM ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chair and CEO Sara Bonstein - CFO Conference Call Participants Jason Zemansky - Bank of America Jeff Hung - Morgan Stanley Andrea Tan - Goldman Sachs Judah Frommer - Credit Suisse Joseph Schwartz - SVB Securities Stephen Willey - Stifel Leon Wang - Barclays Graig Suvannavejh - Mizuho Securities Jennifer Kim - Cantor Fitzgerald Operator Hello everyone and welcome the Insmed Fourth Quarter and Full Year 2022 Financial Results. My name is Nadia and I'll be coordinating the call today.
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
23 февр 2023 г. в 10:32
Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?